AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20602474 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior ischemia on preoperative imaging
Number of subjects: 109
Study 19873914 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp point injection of 0.5‐1 mL brain protein hydrolysate into acupoints (Baihui (GV 20), Fengchi (GB 20), motor area)
Number of subjects: 120
Study 19873914 — intervention group
Group type: COMPARATOR
Intervention: Intravenous drip of 10 mL brain protein hydrolysate
Number of subjects: 120
Study 18294442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg every 12 h for 10 days)
Number of subjects: 61
Study 18294442 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (100 mg every 6 h for 10 days)
Number of subjects: 61
Study 18294442 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) (160/800 mg every 12 h for 10 days)
Number of subjects: 61
Study 15591651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) at 10 mg/kg
Number of subjects: 40
Study 15591651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11204663 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin combined with fluorouracil (5‐FU)/leucovorin
Number of subjects: 0
Study 11204663 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin as monotherapy
Number of subjects: 0
Study 11204663 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin combined with 5‐FU and leucovorin
Number of subjects: 0
Study 11204663 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin in advanced colorectal cancer
Number of subjects: 0
Study 11204663 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCTG N9741 trial
Number of subjects: 0
Study 11204663 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCTG N9841 trial
Number of subjects: 0
Study 11204663 — intervention group
Group type: EXPERIMENTAL
Intervention: NSABP C‐07 adjuvant trial
Number of subjects: 0
Study 9306144 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic Quantification (AQ)
Number of subjects: 16
Study 9306144 — intervention group
Group type: COMPARATOR
Intervention: Doppler echocardiography
Number of subjects: 16
Study 8100910 — intervention group
Group type: EXPERIMENTAL
Intervention: IIIB-rgp120/HIV-1 300 micrograms
Number of subjects: 28
Study 8100910 — intervention group
Group type: EXPERIMENTAL
Intervention: IIIB-rgp120/HIV-1 100 micrograms
Number of subjects: 28
Study 8100910 — intervention group
Group type: COMPARATOR
Intervention: Alum adjuvant alone
Number of subjects: 28
Study 3555050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 23
Study 3555050 — intervention group
Group type: COMPARATOR
Intervention: Beta-lactam antibiotics
Number of subjects: 23
Study 31171879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib, trametinib, and pembrolizumab
Number of subjects: 15
Study 28596447 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy plus IV r‐tPA
Number of subjects: 108
Study 28596447 — intervention group
Group type: COMPARATOR
Intervention: IV r‐tPA alone
Number of subjects: 108
Study 25661122 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 D toric IOL
Number of subjects: 128
Study 25661122 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 D, 2.00 D, and 2.75 D toric IOLs (aggregate)
Number of subjects: 128
Study 25661122 — intervention group
Group type: COMPARATOR
Intervention: Nontoric accommodating IOL (Crystalens)
Number of subjects: 128
Study 25661122 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric IOL
Number of subjects: 128
Study 23827859 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert® MTB/RIF test on pleural fluid
Number of subjects: 67
Study 21872935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg)
Number of subjects: 1298
Study 21872935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.3 mg)
Number of subjects: 1298
Study 21872935 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (verteporfin photodynamic therapy [PDT] and sham intravitreal injections)
Number of subjects: 1298
Study 21872935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 1298
Study 21872935 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 1298
Study 21872935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1298
Study 19482341 — intervention group
Group type: EXPERIMENTAL
Intervention: 4250 IU/day of parnaparin
Number of subjects: 66
Study 19482341 — intervention group
Group type: EXPERIMENTAL
Intervention: 6400 IU/day of parnaparin
Number of subjects: 66
Study 17274862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine 4% solution
Number of subjects: 108
Study 17274862 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine 2% plus adrenaline
Number of subjects: 108
Study 15483279 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 345
Study 15483279 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 345
Study 12546311 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral granisetron plus intravenous dexamethasone (gran/dex)
Number of subjects: 24
Study 12546311 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide plus intravenous dexamethasone (met/dex)
Number of subjects: 24
Study 10051936 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal lidocaine (0.4 ml lidocaine 8% spray)
Number of subjects: 72
Study 10051936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (32 mg)
Number of subjects: 72
Study 10051936 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 3% (no pretreatment)
Number of subjects: 72
Study 10051936 — intervention group
Group type: COMPARATOR
Intervention: Control group (isoflurane maintained at 1.0%)
Number of subjects: 72
Study 7981577 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens opposed by medrogestone
Number of subjects: 43
Study 2513143 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (median dose 300 mg/day)
Number of subjects: 64
Study 2513143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 30188943 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use disorder (AUD) cohort
Number of subjects: 11639
Study 30188943 — intervention group
Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 11639
Study 28421732 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute fluid restriction (AR)
Number of subjects: 34
Study 28421732 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative volume redistribution (RR)
Number of subjects: 34
Study 28421732 — intervention group
Group type: COMPARATOR
Intervention: Both AR and RR
Number of subjects: 34
Study 28421732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pringle maneuver
Number of subjects: 34
Study 25747680 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD group
Number of subjects: 30
Study 25747680 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study 23353795 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb RIPC
Number of subjects: 62
Study 21331977 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychotherapy
Number of subjects: 0
Study 19709851 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-session standard CBT (n=33)
Number of subjects: 100
Study 19709851 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-session group CBT (n=35)
Number of subjects: 100
Study 19709851 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-session brief CBT (n=32)
Number of subjects: 100
Study 19709851 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 100
Study 17095725 — intervention group
Group type: EXPERIMENTAL
Intervention: Rho kinase inhibitor, fasudil
Number of subjects: 29
Study 17095725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 14707020 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 127
Study 14707020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 11342364 — intervention group
Group type: EXPERIMENTAL
Intervention: CEMP (cyclophosphamide, etoposide, mitoxantrone and prednisone) chemotherapy protocol
Number of subjects: 139
Study 11342364 — intervention group
Group type: EXPERIMENTAL
Intervention: CEMP chemotherapy protocol
Number of subjects: 139
Study 9385232 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi Fowler position
Number of subjects: 26
Study 9385232 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 26
Study 9385232 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 degrees laterally inclined position
Number of subjects: 26
Study 9385232 — intervention group
Group type: COMPARATOR
Intervention: 90 degrees side lying position
Number of subjects: 26
Study 9385232 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene‐urethane mattress
Number of subjects: 26
Study 9385232 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital mattress
Number of subjects: 26
Study 7936476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10mg, 20mg, 40mg daily)
Number of subjects: 24
Study 7936476 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25mg, 50mg, 100mg daily)
Number of subjects: 24
Study 2847567 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg of ethanol
Number of subjects: 36
Study 2847567 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 ml/kg of ethanol
Number of subjects: 36
Study 2847567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 14155162 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide (2 mg, three times a day orally for 5 weeks)
Number of subjects: 13
Study 14155162 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical dosage and duration as methysergide)
Number of subjects: 13
Study 31286645 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV734 125 mg
Number of subjects: 0
Study 31286645 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV734 125 mg (drug in capsule after high-fat meal)
Number of subjects: 0
Study 31286645 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV734 (various doses 2 to 250 mg)
Number of subjects: 0
Study 31286645 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV734 (various doses)
Number of subjects: 0
Study 31596672 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I recurrence (single recurrence in remnant kidney or ipsilateral renal fossa)
Number of subjects: 300
Study 31596672 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II recurrence (single recurrence in ipsilateral vasculature, ipsilateral adrenal gland, or lymph node)
Number of subjects: 300
Study 31596672 — intervention group
Group type: EXPERIMENTAL
Intervention: Type III recurrence (single recurrence in other intra-abdominal soft tissues or organs)
Number of subjects: 300
Study 31596672 — intervention group
Group type: EXPERIMENTAL
Intervention: Type IV recurrence (any combination of Types I-III, or multiple recurrences within a single Type)
Number of subjects: 300
Study 31596672 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-year cancer-specific survival
Number of subjects: 300
Study 31596672 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-year overall survival
Number of subjects: 300
Study 31596672 — intervention group
Group type: EXPERIMENTAL
Intervention: Types I-III recurrences
Number of subjects: 300
Study 29178955 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-descent vaginal hysterectomy (NDVH)
Number of subjects: 147
Study 29178955 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy (TLH)
Number of subjects: 147
Study 29178955 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 147
Study 26151924 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (1470 mg/day) + EPA (147 mg/day)
Number of subjects: 110
Study 26151924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 23541756 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 333611 (0.15 mg, 0.50 mg, 1.50 mg, 3.00 mg)
Number of subjects: 32
Study 23541756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23541756 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 333611
Number of subjects: 32
Study 16573261 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole gel
Number of subjects: 32
Study 16573261 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% metronidazole cream
Number of subjects: 32
Study 16573261 — intervention group
Group type: EXPERIMENTAL
Intervention: metronidazole creams
Number of subjects: 32
Study 16573261 — intervention group
Group type: COMPARATOR
Intervention: petrolatum (negative control)
Number of subjects: 32
Study 14613285 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation (two 1.5-hour sessions)
Number of subjects: 242
Study 14613285 — intervention group
Group type: COMPARATOR
Intervention: Print materials about disability employment issues and resources by mail (Control)
Number of subjects: 242
Study 8746863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense multidisciplinary management
Number of subjects: 333
Study 1936348 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste and mouthrinsing
Number of subjects: 44
Study 1936348 — intervention group
Group type: COMPARATOR
Intervention: NaF toothpaste and mouthrinsing
Number of subjects: 44
Study 6214216 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrasive cleaner
Number of subjects: 44
Study 6214216 — intervention group
Group type: COMPARATOR
Intervention: Cleansing agent without abrasive granules
Number of subjects: 44
Study 29206921 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg modafinil
Number of subjects: 22
Study 29206921 — intervention group
Group type: COMPARATOR
Intervention: 60 mg methylphenidate
Number of subjects: 22
Study 29206921 — intervention group
Group type: COMPARATOR
Intervention: 125 mg 3,4‐methylenedioxymethamphetamine
Number of subjects: 22
Study 28212471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac and nifedipine
Number of subjects: 150
Study 28212471 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac and tamsulosin
Number of subjects: 150
Study 26374918 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study 26374918 — intervention group
Group type: COMPARATOR
Intervention: Traditional diuretic therapy
Number of subjects: 0
Study 23349882 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta (IFNB) treatment
Number of subjects: 88
Study 21592048 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg RSG XR
Number of subjects: 2981
Study 21592048 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg RSG XR
Number of subjects: 2981
Study 21592048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2981
Study 18708299 — intervention group
Group type: EXPERIMENTAL
Intervention: sLORETA
Number of subjects: 0
Study 16175957 — intervention group
Group type: EXPERIMENTAL
Intervention: Apartment-based breast cancer education program
Number of subjects: 345
Study 16175957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 345
Study 12840087 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous peripheral-blood hematopoietic progenitor-cell transplantation (6 g of cyclophosphamide, 480 mg of thiotepa, 1600 mg of carboplatin)
Number of subjects: 885
Study 12840087 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy (FEC every three weeks for five courses)
Number of subjects: 885
Study 12840087 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy in patients with 10 or more positive nodes
Number of subjects: 885
Study 12840087 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy in patients with 10 or more positive nodes
Number of subjects: 885
Study 11043056 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (loading dose of 100 mg orally for three days, followed by 20 mg daily)
Number of subjects: 0
Study 11043056 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate or sulphasalazine (previous treatments)
Number of subjects: 0
Study 9091856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophan dialysis membrane
Number of subjects: 10
Study 9091856 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone dialysis membrane
Number of subjects: 10
Study 9091856 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone membranes
Number of subjects: 10
Study 2069245 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural pethidine 25 mg in normal saline
Number of subjects: 94
Study 2069245 — intervention group
Group type: COMPARATOR
Intervention: Normal saline alone (control)
Number of subjects: 94
Study 7092423 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed, supervised exercise training program
Number of subjects: 651
Study 7092423 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 651
Study 31001692 — intervention group
Group type: EXPERIMENTAL
Intervention: EASE (Emotion And Symptom-focused Engagement)
Number of subjects: 42
Study 31001692 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 42
Study 31422065 — intervention group
Group type: EXPERIMENTAL
Intervention: Goals of Patient Care (GOPC) process
Number of subjects: 326
Study 31422065 — intervention group
Group type: COMPARATOR
Intervention: Control (Advance Care Planning alone)
Number of subjects: 326
Study 27633651 — intervention group
Group type: EXPERIMENTAL
Intervention: Multigrowth factor (MGF) cream
Number of subjects: 20
Study 27633651 — intervention group
Group type: COMPARATOR
Intervention: Control cream
Number of subjects: 20
Study 26443993 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492
Study 26443993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study 25057201 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory attention
Number of subjects: 0
Study 25057201 — intervention group
Group type: COMPARATOR
Intervention: Visual attention
Number of subjects: 0
Study 21919966 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost administered for seven days after transplantation
Number of subjects: 80
Study 21919966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iloprost treatment)
Number of subjects: 80
Study 19180065 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual lifestyle treatment program
Number of subjects: 39
Study 19180065 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard lifestyle treatment program
Number of subjects: 39
Study 19180065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle treatment program
Number of subjects: 39
Study 17728363 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) (1.5-2.0 g/day)
Number of subjects: 20
Study 17728363 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (CTX) (0.75-1.0 g/m2)
Number of subjects: 20
Study 15678245 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP (60 pmol/100 mL FAV/min)
Number of subjects: 11
Study 15678245 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term infusions of ANP
Number of subjects: 11
Study 15678245 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term infusions of ANP
Number of subjects: 11
Study 15678245 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infusion of ANP, BNP, and CNP
Number of subjects: 11
Study 12661246 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy
Number of subjects: 124
Study 12661246 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined medicamentous prophylactics with Sandostatin and Verapamil
Number of subjects: 124
Study 10037839 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP administered after operation until leaving ICU
Number of subjects: 40
Study 10037839 — intervention group
Group type: COMPARATOR
Intervention: No hANP administered (Control)
Number of subjects: 40
Study 7619666 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dextromethorphan 30 mg
Number of subjects: 20
Study 7619666 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dextromethorphan (1, 3, and 30 mg)
Number of subjects: 20
Study 7619666 — intervention group
Group type: COMPARATOR
Intervention: Oral matched placebo
Number of subjects: 20
Study 7619666 — intervention group
Group type: COMPARATOR
Intervention: Matched inhaled placebo
Number of subjects: 20
Study 2244080 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible group sequential testing using a Lan and DeMets procedure with permutation test
Number of subjects: 0
Study 2244080 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic curtailment ideas
Number of subjects: 0
Study 736254 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1000 Adrenaline
Number of subjects: 100
Study 736254 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Cocaine
Number of subjects: 100
Study 736254 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Cocaine
Number of subjects: 100
Study 736254 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Cocaine/1:1000 Adrenaline
Number of subjects: 100
Study 736254 — intervention group
Group type: COMPARATOR
Intervention: 5% Cocaine, 10% Cocaine, 5% Cocaine/1:1000 Adrenaline
Number of subjects: 100
Study 31518355 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-PATH intervention (whole school intervention including teacher, parent, and PE components)
Number of subjects: 564
Study 31518355 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 564
Study 28327453 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation plus active oxybutynin administration
Number of subjects: 66
Study 28327453 — intervention group
Group type: COMPARATOR
Intervention: Active oxybutynin administration
Number of subjects: 66
Study 28327453 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 66
Study 25062908 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy for acute WAD
Number of subjects: 20
Study 23809430 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Hamstring Exercise (NHE)
Number of subjects: 18